Mechanisms
Mechanism pages explain how products and clinical programs are grouped by biological target, pharmacologic class, or treatment approach. They help readers compare the structure of the industry without implying that products are interchangeable or equally appropriate for individual patients.
This area should connect mechanisms to active ingredients, brands, investigational assets, companies, indications studied, delivery formats, and development strategies. Useful mechanism records define the concept in accessible language, then show how it maps to the current and emerging obesity treatment landscape.
Mechanism coverage should remain medically careful and source-aware. Claims about efficacy, safety, dosing, indications, or comparative performance require clear scope and credible references when added to individual records.
This is a starting mechanism-level map for US obesity-treatment products, not treatment guidance. It groups products by broad pharmacologic class so readers can follow relationships among drugs, active ingredients, and companies.
GLP-1 receptor agonists
Section titled “GLP-1 receptor agonists”GLP-1 receptor agonists are incretin-based products that connect obesity treatment to the wider diabetes and cardiometabolic drug market. Wegovy and Saxenda link the class to semaglutide, liraglutide, and Novo Nordisk’s obesity portfolio.
Sources: Current DailyMed Wegovy label, DailyMed Saxenda label search
GIP/GLP-1 receptor agonists engage both incretin-related receptor systems. The full mechanism record connects tirzepatide, Zepbound, Mounjaro, Eli Lilly, and the SURMOUNT program while keeping mechanism, ingredient, product, indication, trial, and approval records distinct.
Sources: GIP/GLP-1 receptor agonist record, current DailyMed Zepbound label
Lipase inhibitors
Section titled “Lipase inhibitors”Lipase inhibitors reduce dietary fat absorption through a gastrointestinal mechanism rather than an incretin pathway. Orlistat links this mechanism to prescription Xenical and nonprescription Alli, making it relevant to both prescription and over-the-counter market structure.
Sources: DailyMed Xenical label search, DailyMed Alli label search
Sympathomimetic/antiepileptic combinations
Section titled “Sympathomimetic/antiepileptic combinations”Sympathomimetic/antiepileptic combinations represent an oral fixed-dose approach outside the incretin and lipase-inhibitor categories. Qsymia connects this class to phentermine/topiramate and to the chronic weight-management product landscape.
Source: DailyMed Qsymia label search
Opioid antagonist/antidepressant combinations
Section titled “Opioid antagonist/antidepressant combinations”Opioid antagonist/antidepressant combinations are another oral fixed-dose category in the US chronic weight-management market. Contrave connects this mechanism grouping to naltrexone/bupropion and to product ownership records that should remain dated and source-specific.
Source: DailyMed Contrave label search